{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:00:52Z","timestamp":1787497252955,"version":"build-2736575974"},"reference-count":99,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01BX006046"],"award-info":[{"award-number":["I01BX006046"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","amjmedsci.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.amjms.2024.08.024","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T12:08:00Z","timestamp":1724846880000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Medication-induced fractures: Screening and treatment strategies"],"prefix":"10.1016","volume":"369","author":[{"given":"Laraib","family":"Javed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aemen","family":"Khakwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uzair","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Beth","family":"Humphrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.amjms.2024.08.024_bib0001","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.1097\/MD.0000000000000647","article-title":"Monitoring of patients on long-term glucocorticoid therapy: a population-based cohort study","volume":"94","author":"Fardet","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"26","key":"10.1016\/j.amjms.2024.08.024_bib0002","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1056\/NEJMcp1800214","article-title":"Glucocorticoid-induced osteoporosis","volume":"379","author":"Buckley","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.amjms.2024.08.024_bib0003","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","article-title":"Oral corticosteroids and fracture risk: relationship to daily and cumulative doses","volume":"39","author":"van Staa","year":"2000","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.amjms.2024.08.024_bib0004","doi-asserted-by":"crossref","first-page":"564","DOI":"10.4158\/GL-2020-0524","article-title":"American association of clinical endocrinologists\/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis- 2020 update executive summary","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocrine Practice: Off J Am Coll Endocrinolo Am Assoc Clin Endocrinol"},{"issue":"12","key":"10.1016\/j.amjms.2024.08.024_bib0005","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1002\/acr.25240","article-title":"2022 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"75","author":"Humphrey","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.amjms.2024.08.024_bib0006","doi-asserted-by":"crossref","DOI":"10.1177\/14791641211011016","article-title":"Safety of four SGLT2 inhibitors in three chronic diseases: a meta-analysis of large randomized trials of SGLT2 inhibitors","volume":"18","author":"Qiu","year":"2021","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.amjms.2024.08.024_bib0007","first-page":"239","article-title":"SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives","volume":"12","author":"Gurgle","year":"2016","journal-title":"Vasc Health Risk Manag"},{"issue":"1","key":"10.1016\/j.amjms.2024.08.024_bib0008","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus","volume":"101","author":"Watts","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.amjms.2024.08.024_bib0009","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2903","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis","volume":"33","author":"Ruanpeng","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"10.1016\/j.amjms.2024.08.024_bib0010","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.diabet.2019.01.010","article-title":"Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials","volume":"45","author":"Cheng","year":"2019","journal-title":"Diabetes Metab"},{"issue":"1","key":"10.1016\/j.amjms.2024.08.024_bib0011","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1210\/jc.2015-1860","article-title":"Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.amjms.2024.08.024_bib0012","article-title":"Effect of drugs used in pharmacotherapy of type 2 diabetes on bone density and risk of bone fractures","volume":"60","author":"Wikarek","year":"2024","journal-title":"Medicina (Kaunas)"},{"issue":"2","key":"10.1016\/j.amjms.2024.08.024_bib0013","doi-asserted-by":"crossref","first-page":"e3100","DOI":"10.1002\/dmrr.3100","article-title":"Diabetes pharmacotherapy and effects on the musculoskeletal system","volume":"35","author":"Kalaitzoglou","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"issue":"10","key":"10.1016\/j.amjms.2024.08.024_bib0014","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1007\/s00125-015-3660-2","article-title":"The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis","volume":"58","author":"Billington","year":"2015","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.amjms.2024.08.024_bib0015","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jos.2021.11.005","article-title":"Rosiglitazone induces adipogenesis of both marrow and periosteum derived mesenchymal stem cells during endochondral fracture healing","volume":"28","author":"Mehta","year":"2023","journal-title":"J Orthop Sci"},{"issue":"5","key":"10.1016\/j.amjms.2024.08.024_bib0016","doi-asserted-by":"crossref","first-page":"377","DOI":"10.4093\/dmj.2017.41.5.377","article-title":"Effects of lobeglitazone, a novel thiazolidinedione, on bone mineral density in patients with type 2 diabetes mellitus over 52 weeks","volume":"41","author":"Lim","year":"2017","journal-title":"Diabetes Metab J"},{"issue":"11","key":"10.1016\/j.amjms.2024.08.024_bib0017","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1210\/jc.2015-1215","article-title":"Effects of TZD use and discontinuation on fracture rates in ACCORD bone study","volume":"100","author":"Schwartz","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.amjms.2024.08.024_bib0018","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2337\/dc07-2270","article-title":"Rosiglitazone-associated fractures in type 2 diabetes: an analysis from a diabetes outcome progression trial (ADOPT)","volume":"31","author":"Kahn","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjms.2024.08.024_bib0019","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.08.010","article-title":"Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials","volume":"68","author":"Zhu","year":"2014","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.amjms.2024.08.024_bib0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1503\/cmaj.080486","article-title":"Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis","volume":"180","author":"Loke","year":"2009","journal-title":"CMAJ"},{"issue":"9","key":"10.1016\/j.amjms.2024.08.024_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000154","article-title":"The risk of fractures associated with thiazolidinediones: a self-controlled case-series study","volume":"6","author":"Douglas","year":"2009","journal-title":"PLoS Med"},{"issue":"7","key":"10.1016\/j.amjms.2024.08.024_bib0022","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jcpt.13640","article-title":"Osteoporosis or fracture risk associated with thiazolidinedione and proton pump inhibitor co-administration in patients with type 2 diabetes mellitus","volume":"47","author":"Ock","year":"2022","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"10.1016\/j.amjms.2024.08.024_bib0023","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.numecd.2022.10.004","article-title":"Validation of the clinical consensus recommendations on the management of fracture risk in postmenopausal women with type 2 diabetes","volume":"33","author":"Cairoli","year":"2023","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"5","key":"10.1016\/j.amjms.2024.08.024_bib0024","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1532-5415.2009.02195.x","article-title":"Loop diuretic use and rates of hip bone loss and risk of falls and fractures in older women","volume":"57","author":"Lim","year":"2009","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"10.1016\/j.amjms.2024.08.024_bib0025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2796.2005.01585.x","article-title":"Fracture risk in patients treated with loop diuretics","volume":"259","author":"Rejnmark","year":"2006","journal-title":"J Intern Med"},{"issue":"12","key":"10.1016\/j.amjms.2024.08.024_bib0026","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.amjmed.2016.07.013","article-title":"Diuretic use and risk of vertebral fracture in women","volume":"129","author":"Paik","year":"2016","journal-title":"Am J Med"},{"issue":"11","key":"10.1016\/j.amjms.2024.08.024_bib0027","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40266-015-0306-5","article-title":"Antihypertensive medications, loop diuretics, and risk of hip fracture in the elderly: a population-based cohort study of 81,617 Italian patients newly treated between 2005 and 2009","volume":"32","author":"Corrao","year":"2015","journal-title":"Drugs Aging"},{"issue":"2","key":"10.1016\/j.amjms.2024.08.024_bib0028","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00198-014-2979-8","article-title":"Association between loop diuretic use and fracture risk","volume":"26","author":"Xiao","year":"2015","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.1016\/j.amjms.2024.08.024_bib0029","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00198-012-2053-3","article-title":"Diuretic initiation and the acute risk of hip fracture","volume":"24","author":"Berry","year":"2013","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.amjms.2024.08.024_bib0030","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12891-019-2471-x","article-title":"Association between diuretic use and the risk of vertebral fracture after stroke: a population-based retrospective cohort study","volume":"20","author":"Lin","year":"2019","journal-title":"BMC Musculoskelet Disord"},{"issue":"2","key":"10.1016\/j.amjms.2024.08.024_bib0031","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/archinternmed.2008.526","article-title":"Loop diuretic use and fracture in postmenopausal women: findings from the women's health initiative","volume":"169","author":"Carbone","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjms.2024.08.024_bib0032","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.lfs.2018.12.058","article-title":"Proton pump inhibitors therapy and risk of bone diseases: an update meta-analysis","volume":"218","author":"Liu","year":"2019","journal-title":"Life Sci"},{"issue":"3","key":"10.1016\/j.amjms.2024.08.024_bib0033","doi-asserted-by":"crossref","first-page":"141","DOI":"10.11005\/jbm.2018.25.3.141","article-title":"Proton-pump inhibitor use and fracture risk: an updated systematic review and meta-analysis","volume":"25","author":"Nassar","year":"2018","journal-title":"J Bone Metab"},{"issue":"4","key":"10.1016\/j.amjms.2024.08.024_bib0034","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s00198-015-3434-1","article-title":"Proton pump inhibitors and fracture risk: response to comments","volume":"27","author":"Zhou","year":"2016","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.amjms.2024.08.024_bib0035","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1053\/j.gastro.2010.03.055","article-title":"Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients","volume":"139","author":"Corley","year":"2010","journal-title":"Gastroenterology"},{"issue":"24","key":"10.1016\/j.amjms.2024.08.024_bib0036","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture","volume":"296","author":"Yang","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.amjms.2024.08.024_bib0037","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.gastro.2019.04.041","article-title":"Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and\/or aspirin in a randomized, double-blind, placebo-controlled trial","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.amjms.2024.08.024_bib0038","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/archinternmed.2011.20","article-title":"Proton pump inhibitor use and the antifracture efficacy of alendronate","volume":"171","author":"Abrahamsen","year":"2011","journal-title":"Arch Intern Med"},{"issue":"9","key":"10.1016\/j.amjms.2024.08.024_bib0039","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/1756-185X.12866","article-title":"Proton pump inhibitors use and change in bone mineral density","volume":"19","author":"Arj","year":"2016","journal-title":"Int J Rheum Dis"},{"issue":"8","key":"10.1016\/j.amjms.2024.08.024_bib0040","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.3390\/nu5083022","article-title":"Magnesium and osteoporosis: current state of knowledge and future research directions","volume":"5","author":"Castiglioni","year":"2013","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.amjms.2024.08.024_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.semnephrol.2023.151480","article-title":"Lipid and bone effects of heparin use during hemodialysis","volume":"43","author":"Stegmayr","year":"2023","journal-title":"Semin Nephrol"},{"issue":"8","key":"10.1016\/j.amjms.2024.08.024_bib0042","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s11606-016-3603-8","article-title":"Effects of long-term low-molecular-weight heparin on fractures and bone density in non-pregnant adults: a systematic review with meta-analysis","volume":"31","author":"Gajic-Veljanoski","year":"2016","journal-title":"J Gen Intern Med"},{"issue":"8768","key":"10.1016\/j.amjms.2024.08.024_bib0043","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/0140-6736(91)91292-3","article-title":"Heparins, coumarin, and bone density","volume":"338","author":"Monreal","year":"1991","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.amjms.2024.08.024_bib0044","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11657-020-00770-z","article-title":"Trabecular bone score (TBS) and bone mineral density in patients with long-term therapy with warfarin","volume":"15","author":"Marques","year":"2020","journal-title":"Arch Osteoporos"},{"issue":"2","key":"10.1016\/j.amjms.2024.08.024_bib0045","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archinte.166.2.241","article-title":"Risk of osteoporotic fracture in elderly patients taking warfarin: results from the national registry of atrial fibrillation 2","volume":"166","author":"Gage","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjms.2024.08.024_bib0046","article-title":"The interplay between bone and heart health as reflected in medication effects: a narrative review","volume":"19","author":"Trost","year":"2023","journal-title":"Womens Health (Lond)"},{"issue":"1","key":"10.1016\/j.amjms.2024.08.024_bib0047","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afab264","article-title":"Fracture risks in patients with atrial fibrillation treated with different oral anticoagulants: a meta-analysis and systematic review","volume":"51","author":"Xie","year":"2022","journal-title":"Age Ageing"},{"issue":"2","key":"10.1016\/j.amjms.2024.08.024_bib0048","doi-asserted-by":"crossref","first-page":"139","DOI":"10.11005\/jbm.2021.28.2.139","article-title":"A network meta-analysis comparing osteoporotic fracture among different direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation","volume":"28","author":"Khanra","year":"2021","journal-title":"J Bone Metab"},{"key":"10.1016\/j.amjms.2024.08.024_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116000","article-title":"Bone density and quality in patients treated with direct-acting oral anticoagulants versus warfarin","volume":"150","author":"Nalevaiko","year":"2021","journal-title":"Bone."},{"key":"10.1016\/j.amjms.2024.08.024_bib0050","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.896952","article-title":"Comparative Risks of fracture among direct oral anticoagulants and warfarin: a systematic review and network meta-analysis","volume":"9","author":"Tsai","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"10.1016\/j.amjms.2024.08.024_bib0051","doi-asserted-by":"crossref","first-page":"38564","DOI":"10.52965\/001c.38564","article-title":"The use of antidepressants is linked to bone loss: a systematic review and metanalysis","volume":"14","author":"Mercurio","year":"2022","journal-title":"Orthop Rev (Pavia)"},{"issue":"10","key":"10.1016\/j.amjms.2024.08.024_bib0052","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s00228-020-02893-1","article-title":"Alliance between selective serotonin reuptake inhibitors and fracture risk: an updated systematic review and meta-analysis","volume":"76","author":"Kumar","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.amjms.2024.08.024_bib0053","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/gps.4974","article-title":"Selective serotonin reuptake inhibitor and selective serotonin and norepinephrine reuptake inhibitor use and risk of fractures in adults: a systematic review and meta-analysis","volume":"33","author":"Khanassov","year":"2018","journal-title":"Int J Geriatr Psychiatry"},{"issue":"6","key":"10.1016\/j.amjms.2024.08.024_bib0054","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1136\/injuryprev-2014-041483","article-title":"SSRI use and risk of fractures among perimenopausal women without mental disorders","volume":"21","author":"Sheu","year":"2015","journal-title":"Inj Prev."},{"issue":"6","key":"10.1016\/j.amjms.2024.08.024_bib0055","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00198-018-4413-0","article-title":"Effect of selective serotonin reuptake inhibitors on bone mineral density: a systematic review and meta-analysis","volume":"29","author":"Zhou","year":"2018","journal-title":"Osteoporos Int"},{"issue":"1","key":"10.1016\/j.amjms.2024.08.024_bib0056","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.biopsych.2012.11.003","article-title":"Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and function","volume":"74","author":"Hodge","year":"2013","journal-title":"Biol Psychiatry"},{"issue":"4","key":"10.1016\/j.amjms.2024.08.024_bib0057","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/jbmr.3045","article-title":"The selective serotonin reuptake inhibitor fluoxetine directly inhibits osteoblast differentiation and mineralization during fracture healing in mice","volume":"32","author":"Bradaschia-Correa","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.amjms.2024.08.024_bib0058","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejphar.2018.02.026","article-title":"Differential effects of serotonin reuptake inhibitors fluoxetine and escitalopram on bone markers and microarchitecture in Wistar rats","volume":"825","author":"Kumar","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.amjms.2024.08.024_bib0059","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.bone.2014.04.018","article-title":"Association between use of antiepileptic drugs and fracture risk: a systematic review and meta-analysis","volume":"64","author":"Shen","year":"2014","journal-title":"Bone."},{"issue":"8","key":"10.1016\/j.amjms.2024.08.024_bib0060","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jamaneurol.2023.1580","article-title":"Independent associations of incident epilepsy and enzyme-inducing and non-enzyme-inducing antiseizure medications with the development of osteoporosis","volume":"80","author":"Josephson","year":"2023","journal-title":"JAMA Neurol"},{"issue":"1\u20132","key":"10.1016\/j.amjms.2024.08.024_bib0061","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jns.2013.05.005","article-title":"Bone disease during chronic antiepileptic drug therapy: general versus specific risk factors","volume":"331","author":"Beerhorst","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.amjms.2024.08.024_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106619","article-title":"The effects of antiepileptic drugs on bone health: a systematic review","volume":"173","author":"Griepp","year":"2021","journal-title":"Epilepsy Res"},{"issue":"Pt A","key":"10.1016\/j.amjms.2024.08.024_bib0063","article-title":"An explorative literature review of the multifactorial causes of osteoporosis in epilepsy","volume":"100","author":"Diemar","year":"2019","journal-title":"Epilepsy Behav"},{"issue":"10","key":"10.1016\/j.amjms.2024.08.024_bib0064","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1212\/01.wnl.0000324919.86696.a9","article-title":"Antiepileptic drug use and rates of hip bone loss in older men: a prospective study","volume":"71","author":"Ensrud","year":"2008","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.amjms.2024.08.024_bib0065","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2967\/jnmt.113.124685","article-title":"Antiepileptic treatment is associated with bone loss: difference in drug type and region of interest","volume":"41","author":"Salimipour","year":"2013","journal-title":"J Nucl Med Technol"},{"issue":"11","key":"10.1016\/j.amjms.2024.08.024_bib0066","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1111\/epi.12351","article-title":"Prevention of bone loss and vertebral fractures in patients with chronic epilepsy\u2013antiepileptic drug and osteoporosis prevention trial","volume":"54","author":"Lazzari","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.amjms.2024.08.024_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2020.106287","article-title":"Effects of enzyme-inducing antiseizure medication on vitamin D dosing in adult veterans with epilepsy","volume":"161","author":"Menninga","year":"2020","journal-title":"Epilepsy Res"},{"issue":"2","key":"10.1016\/j.amjms.2024.08.024_bib0068","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.yebeh.2003.11.028","article-title":"Treatment of anticonvulsant drug-induced bone disease","volume":"5","author":"Drezner","year":"2004","journal-title":"Epilepsy Behav"},{"issue":"6","key":"10.1016\/j.amjms.2024.08.024_bib0069","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.bone.2007.02.017","article-title":"Cyclosporin A elicits dose-dependent biphasic effects on osteoblast differentiation and bone formation","volume":"40","author":"Yeo","year":"2007","journal-title":"Bone."},{"issue":"5","key":"10.1016\/j.amjms.2024.08.024_bib0070","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1210\/endo-123-5-2571","article-title":"Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration","volume":"123","author":"Movsowitz","year":"1988","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.amjms.2024.08.024_bib0071","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.intimp.2012.03.019","article-title":"Impact of tacrolimus on bone metabolism after kidney transplantation","volume":"13","author":"Luo","year":"2012","journal-title":"Int Immunopharmacol"},{"issue":"9253","key":"10.1016\/j.amjms.2024.08.024_bib0072","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(00)03641-2","article-title":"Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study","volume":"357","author":"Leidig-Bruckner","year":"2001","journal-title":"Lancet"},{"issue":"9268","key":"10.1016\/j.amjms.2024.08.024_bib0073","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(00)04767-X","article-title":"Osteoporosis after organ transplantation","volume":"357","author":"Devendra","year":"2001","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.amjms.2024.08.024_bib0074","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1399-0012.1995.tb00291.x","article-title":"Long-term bone loss after renal transplantation: comparison of immunosuppressive regimens","volume":"9","author":"McIntyre","year":"1995","journal-title":"Clin Transplant."},{"issue":"12","key":"10.1016\/j.amjms.2024.08.024_bib0075","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1093\/ndt\/gfr214","article-title":"Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis\u2013implications for post-transplantation bone disease","volume":"26","author":"Westenfeld","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.amjms.2024.08.024_bib0076","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.bone.2004.07.013","article-title":"Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts","volume":"35","author":"Kneissel","year":"2004","journal-title":"Bone."},{"issue":"6","key":"10.1016\/j.amjms.2024.08.024_bib0077","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100474","article-title":"Kidney transplantation, immunosuppression and the risk of fracture: clinical and economic implications","volume":"4","author":"Kuppachi","year":"2022","journal-title":"Kidney Med"},{"key":"10.1016\/j.amjms.2024.08.024_bib0078","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/413169","article-title":"Current status of research on osteoporosis after solid organ transplantation: pathogenesis and management","volume":"2015","author":"Lan","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.amjms.2024.08.024_bib0079","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","article-title":"Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG","volume":"7","author":"Hadji","year":"2017","journal-title":"J Bone Oncol"},{"issue":"1","key":"10.1016\/j.amjms.2024.08.024_bib0080","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10549-010-1121-7","article-title":"Reversal of skeletal effects of endocrine treatments in the intergroup exemestane study","volume":"124","author":"Coleman","year":"2010","journal-title":"Breast Cancer Res Treat."},{"issue":"4","key":"10.1016\/j.amjms.2024.08.024_bib0081","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mdq541","article-title":"Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial","volume":"22","author":"Eastell","year":"2011","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.amjms.2024.08.024_bib0082","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa463","article-title":"Challenges in preventing bone loss induced by aromatase inhibitors","volume":"105","author":"Rachner","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjms.2024.08.024_bib0083","article-title":"Efficacy of antiresorptive drugs on bone mineral density in post-menopausal women with early breast cancer receiving adjuvant aromatase inhibitors: a systematic review of randomized controlled trials","volume":"11","author":"de Sire","year":"2021","journal-title":"Front Oncol"},{"issue":"9992","key":"10.1016\/j.amjms.2024.08.024_bib0084","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.amjms.2024.08.024_bib0085","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40618-023-02174-5","article-title":"Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors","volume":"47","author":"Antonini","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.amjms.2024.08.024_bib0086","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231173180","article-title":"Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials","volume":"15","author":"Mastrantoni","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.amjms.2024.08.024_bib0087","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/bonekey.2015.85","article-title":"Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical review","volume":"4","author":"Bienz","year":"2015","journal-title":"Bonekey Rep"},{"issue":"2","key":"10.1016\/j.amjms.2024.08.024_bib0088","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41391-020-00296-y","article-title":"Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer","volume":"24","author":"Hussain","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10001","key":"10.1016\/j.amjms.2024.08.024_bib0089","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.amjms.2024.08.024_bib0090","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2024.08.024_bib0091","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1186\/s12885-015-1843-3","article-title":"Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand","volume":"15","author":"Wang","year":"2015","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.amjms.2024.08.024_bib0092","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8010113","article-title":"Effect of androgen-deprivation therapy on bone mineral density in patients with prostate cancer: a systematic review and meta-analysis","volume":"8","author":"Kim","year":"2019","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.amjms.2024.08.024_bib0093","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5694\/j.1326-5377.2011.tb02979.x","article-title":"Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy","volume":"194","author":"Grossmann","year":"2011","journal-title":"Med J Aust"},{"issue":"8","key":"10.1016\/j.amjms.2024.08.024_bib0094","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.amjms.2024.08.024_bib0095","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J Urol"},{"issue":"11","key":"10.1016\/j.amjms.2024.08.024_bib0096","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/art.11283","article-title":"Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy","volume":"48","author":"Van Staa","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.amjms.2024.08.024_bib0097","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/art.22294","article-title":"Fracture risk with intermittent high-dose oral glucocorticoid therapy","volume":"56","author":"De Vries","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.amjms.2024.08.024_bib0098","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00198-010-1524-7","article-title":"Guidance for the adjustment of FRAX according to the dose of glucocorticoids","volume":"22","author":"Kanis","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.amjms.2024.08.024_bib0099","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.thromres.2016.05.016","article-title":"Prolonged low-molecular-weight heparin use during pregnancy and subsequent bone mineral density","volume":"143","author":"Galambosi","year":"2016","journal-title":"Thromb Res"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000296292401440X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000296292401440X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T09:06:27Z","timestamp":1735808787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000296292401440X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S000296292401440X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2024.08.024","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medication-induced fractures: Screening and treatment strategies","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2024.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of Southern Society for Clinical Investigation.","name":"copyright","label":"Copyright"}]}}